Cyclin B1 is the regulatory subunit of M-phase promoting factor, and proper regulation of cyclin B1 is essential for the initiation of mitosis. Increasing evidence indicates that the deregulation of cyclin B1 is involved in neoplastic transformation, suggesting the suppression of cyclin B1 could be an attractive strategy for antiproliferative therapy. In the present work, we analysed the impact of small interfering RNAs (siRNAs) targeted to cyclin B1 on different human tumor cell lines. Cyclin B1 siRNAs reduced the protein level of cyclin B1 in HeLa, MCF-7, BT-474 and MDA-MB-435 tumor cells and efficiently reduced the kinase activity of Cdc2/cyclin B1 in HeLa cells. siRNA-treated cells were arrested in G2/M phase in all tumor cell lines tested. Proliferation of tumor cells from different origins was suppressed by 50-80% 48 h after transfection and apoptosis was increased from 5 to 40-50%. Furthermore, tumor cells showed less colonyforming ability after siRNA treatment. In contrast, primary human umbilical vein endothelial cells exhibited only a slight change in cell cycle, and neither apoptosis nor clear inhibition of proliferation was observed after cyclin B1 siRNA treatment for 48 h. These results indicate that siRNAs against cyclin B1 could become a powerful antiproliferative tool in future antitumor therapy.
Introduction
The proper regulation of cyclin B1, the regulatory subunit of Ser/Thr kinase Cdc2 (cdk1), is essential for the entry into mitosis (Krek and Nigg, 1991) . Increasing evidence demonstrates that cyclin B1 is involved in checkpoint control and that its deregulated expression could contribute to the chromosomal instability observed in human cancer (Jin et al., 1998; Park et al., 2000; Yin et al., 2001; Santana et al., 2002; SarafanVasseur et al., 2002) . Overexpression of cyclin B1 is observed in various carcinomas including esophageal squamous cell carcinoma, laryngeal squamous cell carcinoma and colorectal carcinoma (Dong et al., 2002; Hassan et al., 2002; Takeno et al., 2002; Li et al., 2003) . Furthermore, overexpression of cyclin B1 indicates a poor prognosis and induces resistance to radiotherapy in head and neck squamous cell carcinoma (Hassan et al., 2002; Takeno et al., 2002) . Taken together, these observations indicate that deregulation of cyclin B1 could be involved in neoplastic transformation and possibly in tumorigenesis. Thus, downregulation or depletion of cyclin B1 in tumor cells could be an attractive strategy for antiproliferative therapy.
In recent years, small interfering RNA (siRNA) has become a specific and powerful tool to turn off the expression of target genes (Tuschl, 2002) . In the present work, we used siRNAs targeting cyclin B1 to reduce the expression of cyclin B1, resulting in impaired M-phase promoting factor (MPF) kinase activity, and analysed the impact of these siRNAs on cellular proliferation and apoptosis in tumor cell lines of different origins.
Results
siRNA is a powerful technique to silence gene expression in a sequence-specific manner. Since different siRNAs targeting the same gene vary in efficiency, we designed three siRNAs against the open reading frame of cyclin B1 mRNA, as illustrated in Figure 1a. The three siRNAs were then tested in various tumor cell lines and in primary human umbilical vein endothelial cells (HUVECs) for their impacts on cyclin B1 expression and on cell proliferation.
Cyclin B1 siRNAs reduce the protein expression of cyclin B1 in various human tumor cell lines and in HUVECs
To examine the effect of the three siRNAs on cyclin B1 protein expression in various tumor cell lines, we performed Western blot analysis on cell lines 48 h after transfection with the siRNAs. The protein level of cyclin B1 standardized to the level of b-actin was efficiently decreased in the cervical carcinoma cell line HeLa and in the breast cancer cell lines BT-474, MCF-7 and MDA-MB-435 after transfection with each of the cyclin B1 siRNAs (Figure 1b, upper and lower panels, . Treatment with the transfection reagent oligofectamine alone or with the control green fluorescent protein (GFP) siRNA had almost no effect (Figure 1b, upper and lower panels, lanes 2 and 3). siRNA1 and siRNA3 appeared to be more effective than siRNA2 in inhibiting cyclin B1 expression, although all three siRNAs reduced cyclin B1 expression in the tumor cell lines tested. In HeLa and BT-474 cells, transfection with siRNA1 or Figure 1b , lower left two panels, lanes 4 and 6), and incubation with siRNA2 reduced the level of cyclin B1 to 3-5% compared to the treatment with control GFP siRNA ( Figure 1b , lower left two panels, lane 5). In MCF-7 and MDA-MB-435 cells, 2-5% of cyclin B1 protein remained after incubation with siRNA1 or siRNA3, compared to 45-50% after transfection with siRNA2 ( Figure 1b , lower right two panels). None of the siRNAs affected the protein level of Cdc2, the partner of cyclin B1, in any of the cell lines tested (Figure 1b , all upper panels, lower bands), suggesting these cyclin B1 siRNAs are highly specific. Because of the strong inhibitory effect demonstrated in the Western blot experiments, siRNA3 was selected for examining the temporal impact of siRNA on cyclin B1 protein expression. HeLa cells were treated with siRNA3 or GFP siRNA and harvested at indicated time points for Western blot analysis. As illustrated in Figure 1c , upper and lower panels, the protein level of cyclin B1 standardized with b-actin was already reduced by 50% as early as 6 h after transfection with siRNA3 ( Figure 1c Results of the Western blot analysis in tumor cells transfected with the cyclin B1 siRNAs were corroborated by analysis of cyclin B1 protein expression using indirect immunofluorescence. Signals representing cyclin B1 staining were strongly decreased in HeLa cells treated with cyclin B1 siRNAs, especially siRNA1 or siRNA3, compared to control cells treated with oligofectamine alone or with GFP siRNA (Figure 1d ).
After examination of cyclin B1 protein in different tumor cells, we were interested in the impact of cyclin B1 siRNAs on primary HUVECs. We compared at first the transfection efficiency between HUVECs and HeLa cells by applying control Fl-labelled siRNA against luciferase. The cells were incubated with the labelled luciferase siRNA and flow cytometry analysis was carried out at 6 h after transfection. As shown in Figure 2a , 48.9% of HUVECs were fluorescence-positive whereas 70.6% of HeLa cells were transfected with luciferase siRNA 6 h after transfection. We studied next the protein level of endogenous cyclin B1 in HUVECs after 48 h treatment with cyclin B1 siRNA1 and siRNA3. As in tumor cells, siRNA3 abolished almost the total cyclin B1 protein and only 4% still remained with siRNA1 treatment in HUVECs (Figure 2b , lower panel, lanes 3 and 4).
Depletion of cyclin B1 with siRNA inhibits the proliferation in tumor cells but not in HUVECs As illustrated in Figure 2 , although the transfection rate was lower in HUVECs than in HeLa cells, siRNA1 or siRNA3 was able to downregulate the cyclin B1 expression, as in HeLa cells. Since cyclin B1 is one of the key components for the regulation of cell proliferation, we next analysed the antiproliferative impact of cyclin B1 siRNA on tumor cell line HeLa as well as on primary HUVECs at different time points. Compared to control treatment with GFP siRNA, transfection with siRNA1 or siRNA3 reduced HeLa cell number by 21 and 33% at 24 h, and 48 and 77% at 48 h, respectively. After 72 h, no HeLa cells were detectable with siRNA3 treatment and 58% of HeLa cells remained with siRNA1 treatment ( Figure 3A) . Interestingly, in contrast to HeLa cells, HUVECs showed no clear inhibition of cell proliferation at 24 and 48 h. At 72 h, proliferation was inhibited by 30% with siRNA3 treatment whereas still no reduction was observed with siRNA1 treatment in HUVECs ( Figure 3B ).
In addition to the cervical carcinoma cell line HeLa ( Figure 3C , a), we also examined the inhibitory effect on breast cancer cell line MCF-7 ( Figure 3C To study the dose kinetics of the antiproliferative effect, we treated HeLa cells for 48 h with different concentrations of siRNA3. As shown in Figure 3D , proliferation of HeLa cells was reduced by nearly 50% after incubation with 1 nM of siRNA3. Application of 10 nM of siRNA3 resulted in almost maximum inhibition. Increasing the concentration of siRNA3 from 50 to 500 nM, using the same amount of the transfection reagent oligofectamine, did not result in a further decrease in HeLa cell number.
Downregulation of cyclin B1 induces G2/M arrest in tumor cells
As cyclin B1 is essential for the G2/M transition, we analysed next the cell cycle distribution of siRNAtreated cells using a FACScan flow cytometer. After incubation for 48 h with 50 nM of cyclin B1 siRNA3, 35% of HeLa cells were arrested in G2/M phase, compared to only 10% of control HeLa located in G2/ M phase (Figure 4a and MCF-7 were observed in G2/M (data not shown). In contrast to various tumor cell lines tested, primary HUVECs exhibited only a slight 3% increase in G2/M population after application of siRNA3 (Figure 4b) , which is possibly due to the very slow proliferation rate of HUVECs. The results suggest that the G2/M arrest was mainly induced in tumor cells, but only slightly in HUVECs, despite the protein level of cyclin B1 was reduced in both tumor cells and in primary HUVECs (Figures 1b, c and 2b) .
The cell cycle analysis revealed further that the G2/M arrest of HeLa cells was induced in a dose-dependent manner over a range of 1-50 nM of siRNA3 (Figure 4c , left panel and right lower panels) whereas the cells displayed no change in cell cycle distribution with control medium or oligofectamine alone (Figure 4c , left panel and right upper panels) or GFP siRNA within a range of 500 pM to 500 nM (Figure 4c , left panel and right middle panels).
We used DNA and lamin staining and fluorescence microscopy to examine further the cell cycle distribution and phenotype of cells treated with cyclin B1 siRNAs. Most of cells were arrested at G2 or early prophase, and cells at metaphase, anaphase or telophase were rarely detectable. The few cells that escaped from the G2/M arrest displayed abnormal chromosome condensation (data not shown).
Depletion of cyclin B1 reduced the kinase activity of Cdc2/cyclin B1 in tumor cells and in HUVECs
We next examined the kinase activity of Cdc2/cyclin B1 in siRNA-treated cells. To get enough cellular extracts for kinase assay, HeLa cells were treated only for 24 h with siRNA1 or siRNA3. Antibodies against cyclin B1 were used to precipitate the Cdc2/cyclin B1 complex from the cellular extracts. The kinase activities of Cdc2/ cyclin B1, which were standardized to the amount of HeLa cells were treated with cyclin B1 siRNA1 or siRNA3 or GFP siRNA (GFP) or oligofectamine alone (OF). After 24 h, the cells were lysed and Cdc2/cyclin B1 complex was immunoprecipitated by using antibodies against cyclin B1 from cellular extracts. The kinase assays were carried out with the precipitates in the presence of histone H1 as substrate. The precipitates using normal control IgG (IgG) from control cellular extracts served as a negative control. The precipitates with cyclin B1 antibodies from nocodazole-treated extracts (Noc) as a positive control. (Figure 5a, lanes 3 and 4) . The kinase activity of positive control cells, which were treated with nocodazole for 24 h, was doubled in comparison with the activity in cells treated with GFP siRNA (Figure 5a , lane 5). The data suggest that both siRNA1 and siRNA3 targeting cyclin B1 efficiently reduced the cyclin B1 protein, which is one of the reasons for the impairment of kinase activity of the Cdc2/cyclin B1 complex in HeLa cells. To further elucidate the mechanism for the reduction of kinase activity of Cdc2/cyclin B1, we performed kinase assay using specific cyclin A antibody, as Cdc2/ cyclin A is another important cyclin-dependent kinase (CDK) of G2/M phase. As shown in Figure 5b , the kinase activity of Cdc2/cyclin A was also reduced in the cells treated with siRNA1 and siRNA3. In Western blot analysis with the same cellular extracts for kinase assay (Figure 5b , last panel), the cyclin A protein, which reaches its highest level in G2/M phase, was reduced after siRNA1 or siRNA3 treatment, whereas its partner Cdc2, which keeps a relative constant level through cell cycle, showed no change. According to sequence comparison, both siRNA1 and siRNA3 cannot exert an effect on cyclin A mRNA. The data implicate that, in addition to the direct reduction of the cyclin B1 protein level, the loss of apoptotic G2/M cells induced by the depletion of cyclin B1 should be another reason for the inhibition of kinase activity of Cdc2/cyclin B1.
The cyclin B1 protein was reduced in HUVECs after the treatment with siRNA1 or siRNA3, but only slight G2/M arrest was observed. To shed more light in HUVECs, we carried out kinase assays by using cyclin B1 antibodies for immunoprecipitation from the cells treated with siRNA1 and siRNA3 for 24 h. As shown in Figure 5c , the kinase activities of Cdc2/cyclin B1 in HUVECs were also reduced by 60 and 70% with siRNA1 and siRNA3 treatment for 24 h, respectively.
Treatment with siRNAs triggers apoptosis and reduces the colony-forming ability in HeLa cells
To examine whether arresting cells at G2/M phase leads further to apoptosis, we performed at first the DNA staining in treated HeLa cells, which revealed an increase in cells with typical apoptotic morphology, including nuclear membrane shrinkage, chromatin condensation and fragmentation ( Figure 6A) . Furthermore, the treated HeLa cells were stained with annexin V and propidium iodide (PI) and were analysed with the help of a flow cytometer. After incubation with siRNA3 for , suggesting that more than 50% of the siRNA-treated cells had entered the apoptotic pathway versus 5% of apoptosis in control HeLa cells ( Figure 6B ). It was noted that transfection of HeLa cells with GFP siRNA also induced apoptosis in 15% of HeLa cells. In addition, cell cycle analysis revealed a sub-G1 peak representing the apoptotic cell population (Figure 4a , right panel and lower right panel; Figure 4c , left panel and right lower panels). Interestingly, in contrast to HeLa cells, the primary HUVECs exhibited scarcely an increase in apoptosis after 48 h treatment with siRNA1 or siRNA3 ( Figure 6C ).
The next intriguing question was whether the tumor cells changed their growth ability in an anchorageindependent manner after siRNA treatment. To answer this question, colony-forming assays in soft-agar were performed. HeLa cells treated with siRNA1, siRNA2 and siRNA3 exhibited 50, 50 and 30% of the colonyforming ability, respectively, compared to the cells treated with GFP siRNA ( Figure 6D ). Although the percentage of reduction in colony-forming ability was the same after siRNA1 or siRNA2 treatment ( Figure 6D ), the size and morphology of the colonies varied much ( Figure 6E ). The most changed size and morphology of colonies were seen following treatment with siRNA3 ( Figure 6E ). Similar results were observed in MCF-7 cells after siRNA treatment (data not shown).
Discussion
Aberrant control of CDKs is a central feature in the molecular pathology of cancer. The deregulation of mitosis initiator MPF (Cdc2/cyclin B1) is involved in tumorigenesis. Cyclin B1, the regulatory subunit of MPF, is highly expressed in various primary tumors (Dong et al., 2002; Hassan et al., 2002; Takeno et al., 2002; Li et al., 2003) , and oncogenes c-MYC and H-ras have been shown to induce the cyclin B1 promoter (Yin et al., 2001; Santana et al., 2002) . Overexpression of cyclin B1 could contribute to the chromosomal instability in cancer cells through an alteration of spindle checkpoint (Park et al., 2000; Sarafan-Vasseur et al., 2002) . Taken together, these data suggest that high expression of cyclin B1 plays a role in tumorigenesis and that suppression of the kinase activity of MPF could therefore be an attractive strategy for inhibiting proliferation of tumor cells. Indeed, many groups have attempted to accomplish this by inhibiting directly Cdc2, the catalytic subunit of MPF. Although various inhibitors of Cdc2 (Cdk1) have been tested as potential candidates for tumor therapy, to date most of the inhibitors targeting Cdc2 lack specificity (Davies et al., 2002; Knockaert et al., 2002 ). An alternative approach for suppression of MPF kinase activity is to target cyclin B1, as depletion of cyclin B1 could specifically inhibit the kinase activity of Cdc2 and further suppress the proliferation of tumor cells.
With this study, we demonstrate for the first time that downregulation of cyclin B1 is an effective and specific approach to inhibit the enzymatic activity of MPF and inhibit proliferation in tumor cells. With three separate siRNAs, we successfully applied RNA silencing to inhibit the expression of cyclin B1. The three siRNAs, designed to target the open reading frame of cyclin B1, reduced the protein level of cyclin B1 in tumor cell lines of different origins (HeLa, MCF-7, BT-474 and MDA-MB-435). Depletion of cyclin B1 inhibited cellular proliferation in cervical carcinoma cell line HeLa, in breast cancer cell line MCF-7, in osteosarcoma cell line Saos-2 and in prostate cancer cell line PC-3. The treated HeLa cells arrested in G2/M phase and the kinase activity of Cdc2/cyclin B1 was almost totally abolished after the treatment with siRNA3. The strong reduction of Cdc2/cyclin B1 kinase activity resulted from the reduction of cyclin B1 protein and the loss of G2/M cells due to apoptosis, since the kinase activity of Cdc2/cyclin A was also reduced after siRNA1 or siRNA3 treatment ( Figure 5b ) and siRNA1 or siRNA3 cannot exert any effect on cyclin A protein according to the sequence comparison. Finally, the colony-forming ability was suppressed in HeLa and MCF-7 cells treated with any of the three cyclin B1 siRNAs.
It is intriguing that although the transfection rate was lower compared to HeLa cells, the treatment of siRNA1 or siRNA3 in HUVECs reduced the cyclin B1 protein (Figure 2b ), inhibited the kinase activity of Cdc2/cyclin B1 ( Figure 5c ) and resulted in a slight G2/M arrest (Figure 4b ). But neither apoptosis and nor clear inhibition of proliferation was observed in HUVECs after the treatment with siRNA1 or siRNA3 for 48 h ( Figures 6C and 3B ). This tumor selective effect is consistent with previous published data from another pivotal molecule of G2/M phase, polo-like kinase 1 (Plk1). One study revealed that the antibody microinjection targeting Polo-like kinase (Plk1) induced mitotic catastrophe in HeLa cells, whereas normal human diploid fibroblasts Hs68 only arrested in the G2 phase of the cell cycle (Lane and Nigg, 1996) . Moreover, dominant-negative Plk1 caused mitotic catastrophe and apoptosis in most tumor cell lines tested but spared the normal cells (Cogswell et al., 2000) . Finally, the strong antiproliferative effect and apoptosis were also observed in tumor cells by applying RNA interference to silence the function of Plk1 (SpankuchSchmitt et al., 2002; Liu and Erikson, 2003) , but not in normal primary human mammary epithelial cells (HMEC) (Spankuch-Schmitt et al., 2002) . Collectively, the data imply that normal cells, which are usually not in cycling and contain very low Plk1 protein, are not sensitive to the downregulation of Plk1 by exhibiting only reversible G2/M arrest and hardly apoptosis. In contrast, the aggressive proliferation of tumor cells is dependent on Plk1 molecule and its downregulation drives the tumor cells to a mitotic catastrophe leading to a strong apoptosis. This could be also the case for cyclin B1, the depletion of which results in apoptosis only in tumor cells but not in normal HUVECs, since cyclin B1, like Plk1, is another essential molecule for G2/M phase and is also highly expressed in many primary tumor cells. The tumor selective apoptosis of cyclin B1 siRNA would be an advantage in future antiproliferative therapy.
Previous studies have demonstrated that different siRNAs targeting the same gene reduce mRNA and protein levels to different degrees, and that the effect of the same siRNA can vary in different cell lines, possibly reflecting the genetic context in each individual tumor cell line (McManus and Sharp, 2002; Spankuch-Schmitt et al., 2002) . We observed similar variability with three siRNAs targeting cyclin B1. Reduced accessibility of the targeted mRNA to siRNA2 may explain the limited effect exhibited by siRNA2. In inducing apoptosis, inhibiting cellular proliferation, arresting cells in G2/M phase and impairing colony-forming ability, the most efficient siRNA we tested was siRNA3, followed by siRNA1 in HeLa cells. In contrast, siRNA1 was the most efficient in MCF-7 cells in inhibiting cell proliferation and kinase activity of MPF ( Figure 3C , b and data not shown). Another observation was that siRNA1 and siRNA3 varied in their antiproliferative effect, although both siRNA1 and siRNA3 abolished cyclin B1 protein and the kinase activity of Cdc2/cyclin B1 almost completely in HeLa cells (Figures 1b and 5a ). This discrepancy is possibly due to the high sensitivity of HeLa cells to siRNAs targeting cyclin B1. Application of lower concentration (e.g. 5-10 nM) will distinguish siRNA1 from siRNA3 in efficacy of reducing cyclin B1 protein and the kinase activity of Cdc2/cyclin B1 in HeLa cells.
The Cdc2/cyclin B1 complex controls the nuclear envelope breakdown and chromosomal condensation. Phosphorylation of nuclear lamins by Cdc2/cyclin B during late prophase leads to depolymerization and breakdown of the nuclear membrane into small vesicles. We observed that most HeLa cells treated with cyclin B1 siRNA were in G2 phase or early prophase, showing big round nuclei with an intact nuclear membrane. This observation suggests that depletion of cyclin B1 with siRNA inhibits the kinase activity of Cdc2/cyclin B1 and allows the nuclear lamins to remain unphosphorylated, ensuring an intact membrane structure. Impairment of nuclear membrane disassembly should lead to an arrest in G2 or early prophase, thereby preventing the cells from undergoing further mitotic progression. We rarely detected mitotic cells in metaphase, anaphase or telophase after treatment with cyclin B1 siRNA, and the few cells that escaped G2 arrest displayed abnormal chromosomal condensation. Deregulation of nuclear membrane breakdown and abnormal chromosomal condensation eventually trigger apoptosis in tumor cells.
siRNA-mediated interference of gene expression has emerged as one of the most specific new tools to knock out molecules involved in tumorigenesis. Our data show that the application of siRNAs targeting cyclin B1 is a specific and efficient technique to abolish the protein expression of cyclin B1, to impair Cdc2/cyclin B1 kinase activity and finally to inhibit proliferation of tumor cells. In combination with other agents, siRNA against cyclin B1 might become a potential antitumor therapeutic agent, particularly in the treatment of cancers associated with high levels of cyclin B1.
Materials and methods

Cell culture
The tumor cell lines BT-474 (breast), MDA-MB-435 (breast), HeLa (cervix), MCF-7 (breast), Saos-2 (osteosarcoma) and PC-3 (prostate) were obtained from DSMZ (Braunschweig, Germany). Ham's F12 and fetal calf serum (FCS) were purchased from PAA Laboratories (Co¨lbe, Germany). Dulbecco's modified Eagle's medium (DMEM), RPMI 1640, phosphate-buffered saline (PBS), Opti-MEM I, oligofectamine, glutamine, penicillin, streptomycin and trypsin were obtained from Invitrogen (Karlsruhe, Germany). All cell lines were cultured according to the supplier's instructions.
HUVECs were derived from umbilical cords using standard methods. Briefly, an umbilical vein was cannulated with a sterile needle and perfused with PBS to remove remaining blood for subsequent incubation with a-chymotrase (Strathmann AG, Hamburg, Germany) at a concentration of 1 mg/ml for 10 min at room temperature. The a-chymotrase solution containing endothelial cells was flushed from the cord by perfusion with RPMI 1640 medium. Cells were centrifuged, resuspended and cultured in RPMI 1640 medium containing 75 mg/ml endothelial cell growth supplement (ECGS) (SigmaAldrich, Schnelldorf, Germany). Control siRNAs targeting GFP and luciferase GL2 (Fl-labelled) were purchased from Dharmacon. All siRNAs were 21 nucleotides in length and contained symmetric 3 0 overhangs of two deoxythymidines. Cells were transfected with siRNAs using a modified oligofectamine protocol (Invitrogen), in which the volume of oligofectamine was reduced to one-third the recommended volume in order to limit toxic effects. In brief, 1 day prior to transfection, cells were seeded without antibiotics to a density of 50-60%. In all experiments except the analysis of dose kinetics, cells were transfected with siRNAs at a concentration of 50 nM. Control cells were treated with Opti-MEM I alone or with oligofectamine. Cells were harvested 48 h after siRNA treatment for cell cycle analysis, Western blots, immunofluorescence staining, and 24 h after siRNA treatment for kinase assay and determination of cell numbers using a hemacytometer. A time kinetics of protein expression and proliferation was carried out at 6, 12, 24, 48 and 72 h after transfection with siRNAs. The dose kinetics assay for cellular proliferation was performed with siRNA concentrations ranging from 500 pM to 500 nM at 48 h.
siRNAs and in vitro transfection
Western blot analysis
Mouse monoclonal antibodies against cyclin B1 (1 : 1000), Cdc2 (1 : 1000), rabbit polyclonal antibodies against cyclin A (1 : 1000) and goat anti-mouse or anti-rabbit secondary antibodies (1 : 2000) were purchased from Santa Cruz (Heidelberg, Germany). Mouse monoclonal antibodies against b-actin (1 : 100 000) were obtained from Sigma-Aldrich (Taufkirchen, Germany). For Western blot analysis in HUVECs, we used 30 mg of cellular extracts (15 mg of tumor cellular extract) and higher concentration of antibodies: antibodies against cyclin B1, 1: 200; antibodies against Cdc2, 1 : 250; and antibodies against b-actin, 1 : 40 000. Western blot analysis was performed as described (Spankuch-Schmitt et al., 2002) .
Analysis of cell cycle, apoptosis and subcellular localization of cyclin B1
Cell viability was assessed by Trypan blue staining. Cell cycle was analysed using a FACScan apparatus (BD Biosciences, Heidelberg, Germany), as described (Yuan et al., 2002a) . Apoptosis was assessed using Vybrantt apoptosis assay kit (annexin V and PI staining) according to manufacturer's instructions (Molecular Probes, Leiden, the Netherlands). Indirect immunofluorescence for subcellular cyclin B1 localization and DNA staining was carried out as previously described (Yuan et al., 2002b) .
Kinase assay in vitro
Cells were transfected with siRNAs targeting cyclin B1 for 24 h and lysed using standard techniques (Yuan et al., 2002b) . Antibodies against cyclin B1 or cyclin A (Santa Cruz, Heidelberg, Germany) were used for immunoprecipitation from 600 mg of cellular extracts. A 0.5 mg portion of histone H1 (Calbiochem, Darmstadt, Germany) served as substrate for each reaction, and the assay was performed as previously described (Yuan et al., 2002b) . HeLa cells with 10 ng/ml of nocodazole (Sigma-Aldrich, Schnelldorf, Germany) for 16 h served as a positive control for kinase activity of Cdc2/cyclin B1 or Cdc2/cyclin A.
Soft-agar colony formation assay
Colony-forming assays were performed using standard methods. Briefly, 48 h after transfection with siRNAs, HeLa and MCF-7 cells were seeded in 24-well plates at a density of 200 cells/well into culture medium containing 0.3% agar (Roth, Karlsruhe, Germany) overlaying 0.5% agar. Cells were cultured at 371C with 5% CO 2 , and colonies were counted 3 weeks later using a microscope (Zeiss, Oberkochen, Germany) and photographed. The colony number in control sample was referred as 100% by quantification.
